Provectus Biopharmaceuticals Inc. (PINK:PVCT)
Industry: Healthcare

OFF LIST - 662 consecutive market days: OFF LIST as of 10/16/2013 Through 11/14/2016

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its prescription drug candidates includes PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, the company is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products. Additionally, it develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of various skin cancers. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Current Quote*
Last: $0.030
Change: 0.002
Book: $4.500
Volume: 213,939

As Of: 07/25 14:25 ET
*Quotes delayed by 20min.

Graphs for PVCT


3 Month Graph


6 Month Graph


1 Year Graph